News

Ronald Barkley, Barbara McAneny, Harlan Levine, and Todd Schonherz discuss the challenges and benefits of health care industry consolidation.

The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...

At CPC & CBEx 2023, Dennis R. Holmes, MD, discusses the impacts of delays in time to treatment for patients and how physician can use clinical pathways to provide more efficient treatment.

At CPC & CBEx 2023, Sayeh Lavasani, MD, discussed the different ways clinical pathways can be followed for HER2-positive breast cancer therapies.

To open Friday’s schedule of sessions at the Clinical Pathways Congress & Cancer Care Business Exchange, Lee Blansett, MBA, Executive Vice President for HMP Market Access Insights, discussed critical trends in today’s oncology...

Ruben A. Mesa, DO, and colleagues analyzed changes in total symptom scores and individual symptom scores of patients with myelofibrosis who participated in the SIMPLIFY-1 and SIMPLIFY-2 studies.

In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.

Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.

NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.

Researchers studied data on the outcomes of patients who received a BTKi in first or second line but subsequently discontinued treatment.